Caracterização clínica e epidemiológica da neoplasia prostática nos anos de 2012 a 2014 em um Centro de Oncologia do leste de Minas Gerais

Caracterização clínica e epidemiológica da neoplasia prostática nos anos de 2012 a 2014 em um Centro de Oncologia do leste de Minas Gerais

O câncer de próstata (CaP) é a segunda causa mais comum de câncer em homens. De acordo com o INCA, no Brasil, em 2016, estimam-se aproximadamente 61.200 novos casos de câncer de próstata. Objetivo: Identificar as características demográficas e epidemiológicas, bem como dados do estadiamento tumoral...

Full description

Bibliographic Details
Main Author:	Araújo, Renato Martins
Other Authors:	Marumo, Maria Helena Bellini
Format:	Others
Language:	pt
Published:	Biblioteca Digitais de Teses e Dissertações da USP 2017
Subjects:	câncer da próstata epidemiologia epidemiology fatores de risco Gleason score prostate cancer PSA (antígeno prostático específico) PSA (prostate specific antigen) risk factors score de Gleason
Online Access:	http://www.teses.usp.br/teses/disponiveis/85/85131/tde-19092017-094409/

Similar Items

Caracterização clínica e epidemiológica da neoplasia prostática nos anos de 2012 a 2014 em um Centro de Oncologia do leste de Minas Gerais
by: Renato Martins Araújo
Published: (2017)

Relação antígeno prostático específico com hiperplasia prostática benigna e adenocarcinoma prostático em casos de Pernambuco
by: Hermínia Cavalcanti França Ferraz, Graças
Published: (2014)

ASSOCIAÇÃO ENTRE PESO PROSTÁTICO E SCORE DE GLEASON EM PACIENTES PORTADORES DE CÂNCER DE PRÓSTATA SUBMETIDOS A PROSTATECTOMIA RADICAL.
by: Bezerra, Leandro Ferro de Moraes
Published: (2016)

Clinical-morphological characteristics of pathological changes in the prostate
by: Ilić Aleksandra, et al.
Published: (2019-01-01)

RRBP1 is highly expressed in prostate cancer and correlates with prognosis
by: Li T, et al.
Published: (2019-04-01)

The value of Gleason score and prostate-specific antigen level in predicting the need for a baseline nuclear bone scan in patients with newly diagnosed 84 prostate cancer cases
by: Hind Chorfi, et al.
Published: (2015-09-01)

CORRELATION BETWEEN SERUM TESTOSTERONE, BIOCHEMICAL AND CLINICAL MARKERS IN PROSTATE CANCER PATIENTS
by: Bogdan Roussev, et al.
Published: (2016-09-01)

Bone scintigraphy in staging of newly diagnosed prostate cancer in regard of different risk groups
by: Sabina Sevcenco, et al.
Published: (2019-06-01)

Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL
by: Katia R. Leite, et al.
Published: (2008-06-01)

A study of biological determinants of serum prostate specific antigen level in prostatic adenocarcinoma with normal, borderline, and high serum PSA levels
by: Anu Sumi Issac, et al.
Published: (2014-01-01)

Survival Analysis and Prognostic Factors in Prostate Cancer Patients: A Single Center Experience in Eastern Anatolia
by: Ali Yılmaz, et al.
Published: (2020-12-01)

Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens
by: Nelson Gianni de Lima, et al.
Published: (2013-06-01)

Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria
by: Nnabugwu II, et al.
Published: (2016-07-01)

High mortality risk of prostate cancer patients in Asia and West Africa: A systematic review
by: Jude O Okoye
Published: (2020-07-01)

THE ROLE OF CYP17A1 IN ADENOCARCINOMA OF THE PROSTATE AT SARDJITO GENERAL HOSPITAL
by: Dwi Prayogo, et al.
Published: (2020-01-01)

La eficiencia del índice de PSA libre en el diagnóstico del cáncer de próstata
by: José Ortiz, et al.
Published: (2015-01-01)

Expressão do colágeno I, III e metaloproteinase nos diferentes graus de Gleason e estadio patológico do câncer prostático
by: Antonio Henrique de Almeida Duarte
Published: (2010)

Expressão do colágeno I, III e metaloproteinase nos diferentes graus de Gleason e estadio patológico do câncer prostático
by: Antonio Henrique de Almeida Duarte
Published: (2010)

Serum and urinary measurements of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in dogs Mensurações sérica e urinária de fosfatase ácida prostática e antígeno prostático específico em cães
by: R.L. Amorim, et al.
Published: (2004-06-01)

Association between gleason score, psa level, PSAD and prostate volume, in a series of patients with prostate adenocarcinoma
by: Benedetti-Padrón Inés, et al.
Published: (2012-06-01)

Discriminación entre hiperplasia prostática benigna y cáncer de próstata mediante el uso de PSA index en consulta externa de urología
by: Pinedo Pichilingue, Aranza, et al.
Published: (2016)

Correlação entre a graduação histológica de biópsias e do espécimen cirúrgico em câncer da prostata
by: José Cury, et al.

by: Betina Katz, et al.
Published: (2012-12-01)

The accuracy of pathological data for the prediction of insignificant prostate cancer
by: Betina Katz, et al.
Published: (2012-12-01)

Histopathological diagnoses and patterns in transrectal ultrasound-guided prostatic biopsy series from a large tertiary care center in Saudi Arabia
by: Ali A Alsulihem, et al.
Published: (2021-01-01)

A second opinion pathology review improves the diagnostic concordance between prostate cancer biopsy and radical prostatectomy specimens
by: Takanori Maehara, et al.
Published: (2021-01-01)

Comparison of prostate biopsy pathology and radical prostatectomy pathologies
by: Ahmet Camtosun, et al.
Published: (2019-03-01)

Investigation of correlations between different prostate-specific antigen forms and clinical and morphological characteristics of a tumor process in patients with prostate cancer
by: N. S. Sergeeva, et al.
Published: (2015-06-01)

Performance characteristics of prostate-specific antigen density and biopsy primary Gleason score to predict biochemical failure in patients with intermediate prostate cancer who underwent radical prostatectomy
by: Peng C, et al.
Published: (2019-02-01)

THE PROGNOSTIC VALUE OF BASELINE PSA BLOOD IN THE TREATMENT OF PROSTATE CANCER
by: A. A. Gritskevich, et al.
Published: (2017-02-01)

Expressão da proteína BRCA2 em prostatectomia e sua correlação com a biópsia em pacientes com câncer de próstata
by: Samara Rodrigues Duarte
Published: (2016)

Expressão da proteína BRCA2 em prostatectomia e sua correlação com a biópsia em pacientes com câncer de próstata
by: Duarte, Samara Rodrigues
Published: (2016)

Desenvolvimento de sensores aptaméricos para monitoramento de biomarcadores de células cancerígenas prostáticas
by: Parra, João Paulo Ruiz Lucio de Lima
Published: (2019)

A grading dilemma; Gleason scoring system: Are we sufficiently compatible? A multi center study
by: Yelda Dere, et al.
Published: (2020-01-01)

Prostate cancer: Relationship between vascular diameter, shape and density and Gleason score in needle biopsy specimens
by: Farhad Tadayyon, et al.
Published: (2013-01-01)

Multimodal Radiomic Features for the Predicting Gleason Score of Prostate Cancer
by: Ahmad Chaddad, et al.
Published: (2018-07-01)

Contemporary Distribution of High-Grade Prostate Cancer in the Circumstances of Opportunistic Testing
by: Stojadinovic Milorad M, et al.
Published: (2020-12-01)

Extraprostatic extension of gleason 6 prostate cancer: single center experience
by: Onur Ceylan, et al.
Published: (2021-06-01)

PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study
by: Salvatore M. Bruno, et al.
Published: (2021-05-01)

Comparison of Pathology and Prevalence of Prostate Cancer in Patients with PSA between 4-10 ng/ml
by: A Tabibi, et al.
Published: (2008-01-01)